Pasithea Therapeutics Overview
- Year Founded
-
2020
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
KTTA
- Investments
-
2
- Share Price
-
$0.47
- (As of Thursday Closing)
Pasithea Therapeutics General Information
Description
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Contact Information
Website
www.pasithea.comCorporate Office
- 1111 Lincoln Road
- Suite 500
- Miami Beach, FL 33139
- United States
Corporate Office
- 1111 Lincoln Road
- Suite 500
- Miami Beach, FL 33139
- United States
Pasithea Therapeutics Stock Performance
As of 19-Nov-2026, Pasithea Therapeutics’s stock price is $0.47. Its current market cap is $17.7M with 36.8M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.47 | $0.51 | $0.28 - $2.06 | $17.7M | 36.8M | 709K | -$1.38 |
Pasithea Therapeutics Financials Summary
As of 30-Sep-2026, Pasithea Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (29,190) | 25,665 | (5,372) | (11,490) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (25,617) | (20,092) | (13,679) | (15,275) |
| Net Income | (24,834) | (20,428) | (13,905) | (15,962) |
| Total Assets | 46,490 | 60,240 | 16,065 | 26,117 |
| Total Debt | 0 | 0 | 0 | 82 |
Pasithea Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pasithea Therapeutics Patents
Pasithea Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026112507-A1 | Tablet formulations and uses thereof | Pending | 22-Nov-2024 | ||
| US-20260193221-A1 | Solid forms comprising (5r,6s)-10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide, and compositions comprising and methods of using the same | Pending | 19-Nov-2024 | ||
| WO-2025230866-A1 | Anti-alpha5 integrin antibodies and uses thereof | Pending | 29-Apr-2024 | ||
| AU-2025205728-A1 | 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same | Pending | 05-Jan-2024 | ||
| EP-4836956-A1 | 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1h-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane] 2,2-dioxide stereoisomers, and compositions comprising and methods of using the same | Pending | 05-Jan-2024 | A61P35/00 |
Pasithea Therapeutics Signals
Pasithea Therapeutics Acquisitions (2)
Pasithea Therapeutics’s most recent deal was a Merger/Acquisition with AlloMEK Therapeutics for . The deal was made on 11-Oct-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AlloMEK Therapeutics | 11-Oct-2022 | Merger/Acquisition | Biotechnology | ||
| Alpha-5 Integrin | 21-Jun-2022 | Merger/Acquisition | Biotechnology |
Pasithea Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Pasithea Therapeutics FAQs
-
When was Pasithea Therapeutics founded?
Pasithea Therapeutics was founded in 2020.
-
Where is Pasithea Therapeutics headquartered?
Pasithea Therapeutics is headquartered in Miami Beach, FL.
-
What is the size of Pasithea Therapeutics?
Pasithea Therapeutics has 5 total employees.
-
What industry is Pasithea Therapeutics in?
Pasithea Therapeutics’s primary industry is Drug Discovery.
-
Is Pasithea Therapeutics a private or public company?
Pasithea Therapeutics is a Public company.
-
What is Pasithea Therapeutics’s stock symbol?
The ticker symbol for Pasithea Therapeutics is KTTA.
-
What is the current stock price of Pasithea Therapeutics?
As of 19-Nov-2026 the stock price of Pasithea Therapeutics is $0.47.
-
What is the current market cap of Pasithea Therapeutics?
The current market capitalization of Pasithea Therapeutics is $17.7M.
-
What is Pasithea Therapeutics’s annual earnings per share (EPS)?
Pasithea Therapeutics’s EPS for 12 months was -$1.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process